 Mark Gregory
Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| fms-Like Tyrosine Kinase 3 | 4 | 2022 | 49 | 1.150 |
Why?
| | Proto-Oncogene Proteins c-myc | 7 | 2012 | 167 | 0.840 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 682 | 0.740 |
Why?
| | Benzothiazoles | 3 | 2022 | 40 | 0.700 |
Why?
| | Glutamine | 2 | 2019 | 109 | 0.690 |
Why?
| | Phenylurea Compounds | 3 | 2022 | 112 | 0.660 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 1084 | 0.540 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2022 | 881 | 0.540 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 2 | 2022 | 69 | 0.540 |
Why?
| | Benzeneacetamides | 1 | 2017 | 8 | 0.530 |
Why?
| | Glutaminase | 1 | 2017 | 11 | 0.530 |
Why?
| | Thiadiazoles | 1 | 2017 | 27 | 0.520 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 127 | 0.490 |
Why?
| | Leukemia | 1 | 2019 | 245 | 0.490 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.490 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 69 | 0.470 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2014 | 69 | 0.450 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 2192 | 0.420 |
Why?
| | Energy Metabolism | 1 | 2019 | 935 | 0.380 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 928 | 0.340 |
Why?
| | Philadelphia Chromosome | 1 | 2010 | 18 | 0.320 |
Why?
| | Cell Line, Tumor | 9 | 2022 | 3539 | 0.320 |
Why?
| | NFATC Transcription Factors | 1 | 2010 | 93 | 0.310 |
Why?
| | Protein Kinase Inhibitors | 6 | 2022 | 968 | 0.310 |
Why?
| | Wnt Proteins | 1 | 2010 | 133 | 0.300 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2012 | 81 | 0.290 |
Why?
| | Apoptosis | 10 | 2022 | 2430 | 0.290 |
Why?
| | Tumor Suppressor Protein p14ARF | 2 | 2005 | 7 | 0.280 |
Why?
| | Cell Proliferation | 4 | 2019 | 2494 | 0.280 |
Why?
| | Mice, Inbred NOD | 3 | 2017 | 610 | 0.250 |
Why?
| | Calcium | 2 | 2013 | 1182 | 0.220 |
Why?
| | Cell Survival | 3 | 2019 | 1098 | 0.220 |
Why?
| | Interferons | 1 | 2026 | 188 | 0.220 |
Why?
| | RNA, Small Interfering | 4 | 2016 | 634 | 0.210 |
Why?
| | Ubiquitins | 2 | 2000 | 33 | 0.200 |
Why?
| | Multienzyme Complexes | 2 | 2000 | 67 | 0.200 |
Why?
| | Cysteine Endopeptidases | 2 | 2000 | 73 | 0.200 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2026 | 215 | 0.200 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2182 | 0.190 |
Why?
| | Cell Nucleus | 2 | 2003 | 618 | 0.190 |
Why?
| | Mice | 12 | 2019 | 18329 | 0.190 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 62 | 0.190 |
Why?
| | Peptide Hydrolases | 1 | 2003 | 105 | 0.190 |
Why?
| | Cyclosporine | 3 | 2014 | 265 | 0.190 |
Why?
| | Dendritic Cells | 1 | 2026 | 499 | 0.190 |
Why?
| | Genes, myc | 2 | 2012 | 50 | 0.190 |
Why?
| | Animals | 15 | 2019 | 38030 | 0.170 |
Why?
| | Epididymis | 1 | 2000 | 14 | 0.170 |
Why?
| | Cell Division | 2 | 2004 | 766 | 0.160 |
Why?
| | Hormones | 1 | 2000 | 134 | 0.160 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 556 | 0.140 |
Why?
| | Transcriptome | 1 | 2025 | 1044 | 0.140 |
Why?
| | Signal Transduction | 6 | 2026 | 5221 | 0.140 |
Why?
| | Phosphorylation | 6 | 2022 | 1732 | 0.130 |
Why?
| | Hydrazines | 1 | 2016 | 37 | 0.120 |
Why?
| | Transfection | 4 | 2004 | 938 | 0.120 |
Why?
| | Liver | 1 | 2025 | 1884 | 0.120 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 621 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 431 | 0.120 |
Why?
| | Tumor Microenvironment | 3 | 2026 | 732 | 0.110 |
Why?
| | Glutamic Acid | 1 | 2017 | 251 | 0.110 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
| | RNA Interference | 2 | 2014 | 476 | 0.110 |
Why?
| | Threonine | 2 | 2012 | 46 | 0.110 |
Why?
| | Imatinib Mesylate | 2 | 2014 | 77 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1953 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 919 | 0.100 |
Why?
| | Dasatinib | 2 | 2014 | 57 | 0.100 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.100 |
Why?
| | Thiazoles | 2 | 2014 | 135 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1044 | 0.100 |
Why?
| | Flow Cytometry | 3 | 2014 | 1172 | 0.100 |
Why?
| | Humans | 19 | 2026 | 144261 | 0.100 |
Why?
| | Survival Analysis | 1 | 2016 | 1382 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 240 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2603 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 73 | 0.090 |
Why?
| | Single-Cell Analysis | 2 | 2026 | 356 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2013 | 190 | 0.090 |
Why?
| | Blotting, Western | 2 | 2012 | 1187 | 0.090 |
Why?
| | Cell Line | 4 | 2005 | 2879 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 161 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4556 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2005 | 529 | 0.080 |
Why?
| | Pyrimidines | 2 | 2014 | 532 | 0.080 |
Why?
| | COS Cells | 2 | 2000 | 181 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2012 | 339 | 0.080 |
Why?
| | Amino Acid Substitution | 3 | 2012 | 304 | 0.080 |
Why?
| | Female | 8 | 2026 | 77976 | 0.080 |
Why?
| | Benzamides | 1 | 2010 | 224 | 0.070 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2000 | 159 | 0.070 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 442 | 0.070 |
Why?
| | Mitosis | 2 | 2000 | 199 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 981 | 0.070 |
Why?
| | Piperazines | 1 | 2010 | 380 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2014 | 5988 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 846 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 844 | 0.060 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 154 | 0.050 |
Why?
| | Hepatocytes | 1 | 2025 | 221 | 0.050 |
Why?
| | Binding Sites | 2 | 2004 | 1327 | 0.050 |
Why?
| | Ubiquitin | 1 | 2003 | 86 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2023 | 824 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 292 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2005 | 382 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 2061 | 0.050 |
Why?
| | Everolimus | 1 | 2022 | 111 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2829 | 0.050 |
Why?
| | Mutation | 3 | 2022 | 4085 | 0.040 |
Why?
| | Middle Aged | 3 | 2025 | 35762 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 210 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2005 | 1455 | 0.040 |
Why?
| | Growth Inhibitors | 1 | 2000 | 39 | 0.040 |
Why?
| | Protein Binding | 2 | 2004 | 2270 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 77 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2004 | 2154 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 50 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 276 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2000 | 156 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 148 | 0.040 |
Why?
| | Organ Specificity | 1 | 2000 | 312 | 0.040 |
Why?
| | Mammary Glands, Animal | 1 | 2000 | 128 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2929 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2000 | 193 | 0.040 |
Why?
| | Prostate | 1 | 2000 | 158 | 0.040 |
Why?
| | Uterus | 1 | 2000 | 226 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 449 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2012 | 39 | 0.040 |
Why?
| | Tubulin | 1 | 2000 | 147 | 0.040 |
Why?
| | CHO Cells | 2 | 2012 | 171 | 0.040 |
Why?
| | Ovary | 1 | 2000 | 228 | 0.040 |
Why?
| | Cricetinae | 2 | 2012 | 303 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1782 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 674 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 477 | 0.030 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 862 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 2000 | 592 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5592 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Fibroblasts | 1 | 2000 | 1032 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 75 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2004 | 93 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 204 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 357 | 0.020 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2012 | 20 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2012 | 32 | 0.020 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 70 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2012 | 193 | 0.020 |
Why?
| | Vinblastine | 1 | 2012 | 75 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2012 | 1495 | 0.020 |
Why?
| | Cytarabine | 1 | 2012 | 66 | 0.020 |
Why?
| | Peptide Mapping | 2 | 2004 | 63 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 261 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 116 | 0.020 |
Why?
| | Ubiquitination | 1 | 2012 | 118 | 0.020 |
Why?
| | ras Proteins | 1 | 2013 | 150 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 166 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 253 | 0.020 |
Why?
| | Protein Stability | 1 | 2012 | 178 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 381 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 433 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 251 | 0.020 |
Why?
| | Wnt Signaling Pathway | 1 | 2013 | 210 | 0.020 |
Why?
| | HeLa Cells | 1 | 2012 | 650 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 334 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.020 |
Why?
| | Male | 3 | 2025 | 72035 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 983 | 0.020 |
Why?
| | Brain | 1 | 2000 | 2930 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3119 | 0.020 |
Why?
| | Genomics | 1 | 2013 | 833 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2012 | 4146 | 0.010 |
Why?
| | Okadaic Acid | 1 | 2004 | 15 | 0.010 |
Why?
| | Aged | 1 | 2025 | 25850 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 153 | 0.010 |
Why?
| | Carcinogens | 1 | 2004 | 122 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 177 | 0.010 |
Why?
| | Paclitaxel | 1 | 2004 | 255 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2004 | 252 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 437 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 387 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 765 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 309 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 596 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2026 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 11643 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2000 | 343 | 0.010 |
Why?
| | Microtubules | 1 | 2000 | 286 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7155 | 0.010 |
Why?
| | Adult | 1 | 2014 | 40262 | 0.010 |
Why?
|
|
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|